Navigation Links
Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment
Date:9/23/2009

NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $5 million for research to successfully translate neurotrophic factor advances from pre-clinical and early-phase clinical work into a practical, patient-relevant treatment for Parkinson's disease. The funding will be awarded under a new Directed LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) initiative.

The Foundation's intention is to identify and drive ambitious projects with a clear plan for accelerating trophic factor therapy through the stages of preclinical and clinical development up to and including Phase 2 clinical studies. Also of interest are therapeutic approaches that include evidence that the trophic factor being studied holds potential for neuroregeneration (helping the brain rejuvenate sick cells) and not merely neuroprotection (protecting existing neurons from death).

Neurotrophic factors (also known as trophic factors or growth factors) are specialized proteins that protect and nourish neurons in the brain, including the dopamine neurons that die in Parkinson's disease. They are a high-priority therapeutic target for MJFF, which has committed approximately $20 million to their development to date, because they have shown potential to slow or stop the progression of Parkinson's in the brain -- something no currently available treatment has been proven to do.

In the last several years, preclinical studies and several early-phase clinical trials in neurotrophic factors have shown promise to revolutionize the treatment of PD. Research increasingly indicates that trophics are safe for use in people, and several Phase 1 neurotrophic clinical trials have shown signs of efficacy. But results from all previous trials have been ultimately inconclusive, and no trophic-based approach has yet been demonstrated to be both safe and efficacious in a Phase 2 clinical trial.

"While many unanswered questions remain about the potential of neurotrophic factors as therapies for PD, MJFF continues to regard neurotrophic factor therapy as a promising avenue," said Todd Sherer, PhD, vice president of research programs at MJFF. "We believe the approach deserves additional rigorous investigation in hope of advancing the field from promise to reality -- or at least definitively determining its viability."

This Directed LEAPS program is open to academic and industry researchers. Pre-proposals are due November 18, 2009. Funding is anticipated in June 2010. The full RFA and detailed information on submitting an application are available at www.michaeljfox.org/research.


The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded $149 million in research to date.

    Media contact:
    Holly Barkhymer
    212-509-0995 x242
    hbarkhymer@michaeljfox.org

    Research contact:
    Jamie Eberling, PhD
    212-509-0995 x278
    jeberling@michaeljfox.org
     


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... manufactures practical mobile kitchens, recently announced the debut of their latest mobile kitchen ... Mobile Kitchens provides organizations with modern, high-volume commercial kitchens for use anywhere in ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 Amgen (NASDAQ: AMGN ) will present ... Conference at 9:15 a.m. ET on Wednesday, Feb. 10, 2016, ... W. Meline , executive vice president and chief financial officer ... the presentation can be accessed from the Events Calendar on ... the webcast will also be available on Amgen,s website for ...
(Date:2/5/2016)... 2016  Patients in Alabama seeking ... therapy no longer have to travel out of state. ... Urology Centers of Alabama to provide a total ... qualifying patients. Alabama is ... of prostate cancer using many different modalities. They are the ...
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
Breaking Medicine Technology: